Skip to content
Politically.com Search all
Menu

2025 · 4th Quarter (Oct 1 - Dec 31)

FRESENIUS KABI USA, LLC

Filed by CGCN GROUP, LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
4th Quarter - Report
Posted
Jan 21, 2026
Income
$50,000.00
Expenses
Not reported
Registrant
CGCN GROUP, LLC
Filing UUID
74a2d53d-6061-4c09-962b-3e5c3981d8a8
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MAN · Manufacturing

Buy America legislation, tariffs, and tax incentives.

TAR · Tariff (miscellaneous tariff bills)

Section 232 investigation into pharmaceuticals and unfair trade practices.

TAX · Taxation/Internal Revenue Code

U.S. manufacturing incentives.

TRD · Trade (domestic/foreign)

Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.